Beyond AirXAIR
XAIR
About: Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Employees: 61
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
367% more call options, than puts
Call options by funds: $14K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 45 [Q4 2024] → 43 (-2) [Q1 2025]
6.78% less ownership
Funds ownership: 28.56% [Q4 2024] → 21.78% (-6.78%) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
29% less capital invested
Capital invested by funds: $7.39M [Q4 2024] → $5.24M (-$2.15M) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Research analyst outlook
We haven’t received any recent analyst ratings for XAIR.
Financial journalist opinion
Based on 7 articles about XAIR published over the past 30 days
Neutral
Zacks Investment Research
2 weeks ago
Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Neutral
Seeking Alpha
3 weeks ago
Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Joseph Daniel Downing - Piper Sandler & Co., Research Division Justin Howard Walsh - JonesTrading Institutional Services, LLC, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Corey George Davis - Lifesci Advisors, LLC Operator Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the Fiscal Quarter and Year Ended March 31, 2025.
Negative
Zacks Investment Research
3 weeks ago
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.
Negative
Benzinga
3 weeks ago
Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know
Beyond Air, Inc. XAIR released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures from the quarter.
Neutral
GlobeNewsWire
3 weeks ago
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe, Australia, and the Middle East Appointed Robert Goodman, a commercial focused seasoned healthcare executive, to the Company's Board of Directors Conference call at 4:30 p.m. ET today, June 17 th GARDEN CITY, N.Y.
Neutral
GlobeNewsWire
3 weeks ago
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the submission of a premarket approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for LungFit PH II, the next-generation therapeutic nitric oxide generator.
Neutral
Benzinga
3 weeks ago
Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings
Beyond Air, Inc. XAIR will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.
Neutral
GlobeNewsWire
1 month ago
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.
Neutral
GlobeNewsWire
2 months ago
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder
Neutral
GlobeNewsWire
2 months ago
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease
Charts implemented using Lightweight Charts™